Mohamed E. Ahmed, Giuseppe Reitano, Milad Bonakdarhashemi, Kelly Lehner, Carter Day, Jack Andrews, Eugene Kwon, R. Jeffrey Karnes
{"title":"MAPPING PATTERNS OF RECURRENCE AFTER SALVAGE LYMPH NODE DISSECTION IN PATIENTS WITH METASTATIC PROSTATE CANCER","authors":"Mohamed E. Ahmed, Giuseppe Reitano, Milad Bonakdarhashemi, Kelly Lehner, Carter Day, Jack Andrews, Eugene Kwon, R. Jeffrey Karnes","doi":"10.1016/j.urolonc.2024.12.071","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><div>Salvage lymph node dissection represents one of the rescue treatment options for prostate cancer patients with lymph node recurrence. Nonetheless, patterns of recurrence after salvage lymph node dissection is not well stuided. As such, we thought to study patterns of recurrence in patients with oligometastatic disease identified through C11 choline PET imaging and treated with salvage lymph node dissection.</div></div><div><h3>Methods</h3><div>Utilizing the prospectively maintained C11 choline PET CT scan registry, we identified 116 patients who underwent salvage lymph node dissection for oligometastatic disease detected by C11 choline PET/CT. The salvage lymph node dissection procedures included a bilateral extended template. Recurrence sites following the procedure were classified into five categories: local recurrence, regional lymph node recurrence, non-regional lymph node recurrence, distant recurrence, and bone disease. The median follow-up duration was 90 months.</div></div><div><h3>Results</h3><div>Table 1 presents the clinicopathological variables of the study cohort. Notably, 88% of the cohort had undergone radical prostatectomy as their primary treatment. The majority of patients had 1-2 pathology-proven metastases on C11 choline PET-CT prior to salvage lymph node dissection. Regional lymph nodes were the predominant site of pre-salvage oligometastatic disease, accounting for 70% of cases. Figure 1 illustrates the sites of disease recurrence following salvage lymph node dissection. Regional lymph nodes were the most common site of recurrence, followed by bone disease, non-regional lymph nodes, local recurrence, and distant lymph node metastases. The median time to biochemical recurrence after salvage lymph node dissection was approximately 9 months.</div></div><div><h3>Conclusions</h3><div>Salvage lymph node dissection constitutes one of the salvage treatment options for patients with oligometastatic disease. Presents of recurrence after salvage lymph node dissection is anatomically diverse with regional lymph node represents the most common site of disease recurrence. This findings have implications for guiding subsequent salvage treatment options after salvage lymph node dissections.</div></div>","PeriodicalId":23408,"journal":{"name":"Urologic Oncology-seminars and Original Investigations","volume":"43 3","pages":"Page 28"},"PeriodicalIF":2.3000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Urologic Oncology-seminars and Original Investigations","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1078143924008512","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction
Salvage lymph node dissection represents one of the rescue treatment options for prostate cancer patients with lymph node recurrence. Nonetheless, patterns of recurrence after salvage lymph node dissection is not well stuided. As such, we thought to study patterns of recurrence in patients with oligometastatic disease identified through C11 choline PET imaging and treated with salvage lymph node dissection.
Methods
Utilizing the prospectively maintained C11 choline PET CT scan registry, we identified 116 patients who underwent salvage lymph node dissection for oligometastatic disease detected by C11 choline PET/CT. The salvage lymph node dissection procedures included a bilateral extended template. Recurrence sites following the procedure were classified into five categories: local recurrence, regional lymph node recurrence, non-regional lymph node recurrence, distant recurrence, and bone disease. The median follow-up duration was 90 months.
Results
Table 1 presents the clinicopathological variables of the study cohort. Notably, 88% of the cohort had undergone radical prostatectomy as their primary treatment. The majority of patients had 1-2 pathology-proven metastases on C11 choline PET-CT prior to salvage lymph node dissection. Regional lymph nodes were the predominant site of pre-salvage oligometastatic disease, accounting for 70% of cases. Figure 1 illustrates the sites of disease recurrence following salvage lymph node dissection. Regional lymph nodes were the most common site of recurrence, followed by bone disease, non-regional lymph nodes, local recurrence, and distant lymph node metastases. The median time to biochemical recurrence after salvage lymph node dissection was approximately 9 months.
Conclusions
Salvage lymph node dissection constitutes one of the salvage treatment options for patients with oligometastatic disease. Presents of recurrence after salvage lymph node dissection is anatomically diverse with regional lymph node represents the most common site of disease recurrence. This findings have implications for guiding subsequent salvage treatment options after salvage lymph node dissections.
期刊介绍:
Urologic Oncology: Seminars and Original Investigations is the official journal of the Society of Urologic Oncology. The journal publishes practical, timely, and relevant clinical and basic science research articles which address any aspect of urologic oncology. Each issue comprises original research, news and topics, survey articles providing short commentaries on other important articles in the urologic oncology literature, and reviews including an in-depth Seminar examining a specific clinical dilemma. The journal periodically publishes supplement issues devoted to areas of current interest to the urologic oncology community. Articles published are of interest to researchers and the clinicians involved in the practice of urologic oncology including urologists, oncologists, and radiologists.